Eribulin Enormously Benefits Major Subset of Breast Cancer Patients

By Annette M. Boyle, contributor.

Save to PDF OncologyWomens' Health By

San Antonio—Eribulin is currently the only cancer agent shown to extend overall survival in previously treated patients with breast cancer. While a biomarker to target those likely to benefit most has yet to be identified, Spanish researchers have discovered that patients with HER2-enriched and Lumina B breast cancer subtypes have significantly greater response to eribulin than others.

The researchers presented the results of the phase 2, open-label, single-arm SOLTI1007 study at the 2016 San Antonio Breast Cancer Symposium. SOLTI1007 analyzed the association of pre-treatment expression of RNA in stage I-II HER2-negative breast cancer patients with response to neoadjuvant eribulin delivered intravenously on days 1 and 8 of every 21-day cycle for 4 cycles.


The Data

Researchers enrolled 73 triple negative breast cancer patients and 101 hormone responsive patients between September 2012 and October 2015, of whom 85% completed all 4 cycles.

The team compared baseline and post-treatment formalin-fixed, paraffin-embedded tissue samples for gene expression, PAM50 intrinsic subtype and risk of relapse based on subtype and proliferation (ROR-p). Univariate logistic regression models evaluated the association between each PAM50 signature and pathological complete response in the breast (pCRB).

Overall pCRB was 5.4%, with no significant differences between TNBC and HR+ patients.



Distribution of the subtypes was: Luminal A (27.7%), Luminal B (27.1%), basal-like (40.6%) and HER2-enriched (4.5%). Of those, the HER2-enriched patients had the strongest response to eribulin, with 28.6% achieving pCRB. Luminal B patients had the second highest rates of pCRB at 7.1%. Patients with basal-like tumors had 4.8% pCRB and those with Luminal A type had 2.3%. Patients with tumors at high risk of relapse also had an increased likelihood of pCRB, with 17.1% of those with high ROR-P achieving pCRB compared to just 2.7% of ROR-P medium and 2.2% of ROR-P low results.

HER2-enriched and Luminal B patients were also far more likely to experience subtype change between baseline and surgery, at 60% and 44.1%, respectively, compared to 10.3% of Luminal A patients and 5.4% of those with basal-like tumors.

Abbreviated Author Information

The 2016 annual San Antonio Breast Cancer Symposium, Poster P1-09-09.

Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer


  • Prat A, Cortés J Hospital Clinic i Provincial, Barcelona, Spain;
  • Ortega V, Translational Genomics Group, Vall d´Hebron Institute of Oncolgy, Barcelona;
  • Villagrasa P, Hospital Universitari Vall d' Hebron, Barcelona; SOLTI Breast Cancer Research Group, Barcelona
  • et al.